Cancer and Blood Specialty Clinic

Los Alamitos, CA

Sorting 2 by

Accepting patients

ELEMENT-MDS

Phase 3 Clinical Trial Comparing Luspatercept VS Epoetin Alfa in Patients with Very Low – Intermediate Risk MDS Who Are Not Transfusion Dependent
Learn more
  • Erythroid Maturation Agent (EMA)
  • Erythropoiesis-Stimulating Agent (ESA)
  • Red Blood Cell Stimulant
  • Phase 3

Accepting patients

MAXILUS

A Phase 3b, Open-label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS With IPSS-R Very Low-, Low-, or Intermediate-risk Who Require RBC Transfusions (MAXILUS)
Learn more
  • Erythroid Maturation Agent (EMA)
  • Red Blood Cell Stimulant
  • Phase 3